<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004747</url>
  </required_header>
  <id_info>
    <org_study_id>199/11663</org_study_id>
    <secondary_id>VU-7511</secondary_id>
    <nct_id>NCT00004747</nct_id>
  </id_info>
  <brief_title>Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Assess the efficacy of monthly intravenous mucoid exopolysaccharide&#xD;
      Pseudomonas aeruginosa immune globulin (MEP IGIV) given over 1 year in reducing the frequency&#xD;
      of acute pulmonary exacerbation in patients with cystic fibrosis, mild to moderate pulmonary&#xD;
      disease, and mucoid P. aeruginosa colonization.&#xD;
&#xD;
      II. Assess the effect of MEP IGIV on FEV1, sputum density of mucoid P. aeruginosa, and the&#xD;
      quality of life in these patients.&#xD;
&#xD;
      III. Assess the safety of monthly MEP IGIV. IV. Assess population-based MEP IGIV&#xD;
      pharmacokinetics during chronic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by&#xD;
      participating institution.&#xD;
&#xD;
      Patients are randomly assigned to 1 of 3 groups: low-dose intravenous mucoid&#xD;
      exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IVIG), high-dose MEP IVIG, or&#xD;
      placebo. Therapy is administered every 28 days for 12 months. Treatment is not initiated in&#xD;
      the presence of an acute asthmatic attack.&#xD;
&#xD;
      Concurrent chronic suppressive antibiotics are permitted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1995</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>170</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Bacterial Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mucoid exopolysaccharide P. aeruginosa immune globulin IV</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        Disease Characteristics&#xD;
&#xD;
          -  Cystic fibrosis (CF) documented by pilocarpine iontophoresis sweat chloride greater&#xD;
             than 60 mEq/L FEV1 30%-80% of predicted and within 20% of maximum values obtained in&#xD;
             12 months prior to entry Able to expectorate at least 1 g of sputum within 3 hours at&#xD;
             screening&#xD;
&#xD;
          -  Mucoid Pseudomonas aeruginosa colonization documented in at least 2 serial&#xD;
             expectorated sputum cultures in the year prior to entry Screening specimen meets&#xD;
             requirement for 1 culture&#xD;
&#xD;
          -  Documented exacerbation of respiratory tract infection At least 1 hospitalization&#xD;
             and/or course of parenteral or nebulized antibiotic therapy in each of the 2 years&#xD;
             prior to entry&#xD;
&#xD;
          -  At least 2 serial spirometry tests over at least 6 months prior to entry FEV1 range no&#xD;
             more than 15% relative to maximum value&#xD;
&#xD;
          -  None of the following within 6 months prior to entry: Pseudomonas (Burholderia)&#xD;
             cepacia or atypical mycobacteria in respiratory tract Pulmonary hemorrhage with&#xD;
             greater than 5% drop in hematocrit Pneumothorax requiring chest tube&#xD;
&#xD;
          -  No life-threatening CF sequelae, e.g.: Severe cirrhosis with ascites or bleeding&#xD;
             Severe distal intestinal obstruction syndrome requiring cessation of oral intake&#xD;
             Poorly controlled insulin-dependent diabetes with acetonuria&#xD;
&#xD;
        Prior/Concurrent Therapy&#xD;
&#xD;
          -  No concurrent participation in other investigational protocols&#xD;
&#xD;
          -  No prior investigational P. aeruginosa vaccine&#xD;
&#xD;
          -  At least 45 days since immune globulin or antibacterial monoclonal antibody&#xD;
&#xD;
          -  At least 4 weeks since investigational drugs&#xD;
&#xD;
          -  At least 2 weeks since systemic glucocorticoids&#xD;
&#xD;
          -  No requirement for systemic steroids during first 2 weeks of study&#xD;
&#xD;
        Patient Characteristics&#xD;
&#xD;
          -  Renal: Creatinine less than 2 mg/dL (1.5 mg/dL in patients under 50 kg)&#xD;
&#xD;
          -  No proteinuria&#xD;
&#xD;
          -  No hematuria&#xD;
&#xD;
          -  Cardiovascular: No cor pulmonale or other heart disease requiring chronic diuretics,&#xD;
             afterload reduction, or cardiac glycoside therapy (e.g., digoxin)&#xD;
&#xD;
          -  Immunologic: Endogenous immunoreactive IgA at least 5 mg/dL&#xD;
&#xD;
          -  No hypersensitivity to immune globulin or human albumin&#xD;
&#xD;
          -  No primary or acquired immunodeficiency disease&#xD;
&#xD;
          -  Other: No clinical test abnormal on repeat and inconsistent with CF&#xD;
&#xD;
          -  No smoking 1 month prior to and during study&#xD;
&#xD;
          -  No suspected drug or alcohol abuse within 1 year prior to entry&#xD;
&#xD;
          -  No severe illness that precludes protocol participation&#xD;
&#xD;
          -  No disability, condition, or geographical location that would impair compliance&#xD;
&#xD;
          -  No psychiatric disorder, intellectual deficiency, or other condition that would limit&#xD;
             informed consent&#xD;
&#xD;
          -  Negative pregnancy test required of fertile women&#xD;
&#xD;
          -  Medically acceptable contraception required of fertile women&#xD;
&#xD;
          -  Participating investigators, sub-investigators, study coordinators, and employees of&#xD;
             participating investigators or immediate family members of any of these groups&#xD;
             ineligible&#xD;
&#xD;
          -  Blood/body fluid analyses and other exams within 28 days prior to registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Preston W. Campbell</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>bacterial infections</keyword>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

